表紙
市場調查報告書

EpiCast Report:心臟衰竭 (HF) - 至2025年的流行病學預測

Heart Failure: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 258692
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:心臟衰竭 (HF) - 至2025年的流行病學預測 Heart Failure: Epidemiology Forecast to 2028
出版日期: 2019年12月16日內容資訊: 英文 63 Pages
簡介

在全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本),心臟衰竭 (HF) 確診的發病數量,預計從2015年的1,094,344件,增加到2025年的1,400,377件,以2.80%的年度成長率 (AGR) 增加。

本報告提供全球主要7個國家的心臟衰竭 (HF) 調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 心臟衰竭 (HF) 的流行病學預測
    • 確診的發病數量
    • 確診的患者數
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第3章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER224-19

Heart Failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Heart Failure (HF) commonly occurs in people older than 50 years of age, and severity increases progressively with age. The symptoms can develop quickly, such as in Acute Heart Failure (AHF), at which time the patient needs to be hospitalized. However, in Chronic Heart Failure (CHF), the symptoms develop gradually.

Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan and China) occur in the elderly population, and this is estimated to increase by a further 40% by 2028. The major drivers for this trend include increasing life expectancy, early diagnosis of Heart Failure (HF) by improved screening and detection of Heart Failure (HF), as well as the widespread adoption of effective treatment strategies to manage Heart Failure (HF) patients with multiple comorbidities.

Diagnosed prevalent cases of Chronic Heart Failure (CHF) in the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) are projected to increase from 26.8 million in 2018 to 32.2 million in 2028, at an annual growth rate (AGR) of 2.02%. There were 12.8 million cases of the disease in China in 2018, which represented 47.69% of those in the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The UK had the lowest number of diagnosed prevalent cases in 2018 at 5.50 million.

The substantial increase in comorbidities such as Coronary Artery Disease (CAD) and hypertension may be driving the number of diagnosed prevalent cases to rise in the elderly. It is observed that Heart Failure (HF) with preserved ejection fraction (PEF) is one of the common cardiac complications of longstanding hypertension. In 2018, the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) saw more than half of Chronic Heart Failure (CHF) patients experience Coronary Artery Disease (CAD) or hypertension as a major comorbid condition.

Despite advancements in the treatment of Chronic Heart Failure (CHF), the major unmet needs in elderly Chronic Heart Failure (CHF) patients are improved adherence to treatment guidelines and additional effective therapeutic options to manage Chronic Heart Failure (CHF) with multiple comorbidities. The improvement of screening techniques and diagnostic approaches over the years has led to better diagnoses, as reflected in the increased burden of Chronic Heart Failure (CHF). Effective strategies to prevent lifestyle diseases such as hypertension and diabetes mellitus during early adulthood may help prevent the occurrence of Chronic Heart Failure (CHF) in the elderly.

The latest epidemiology report "Heart Failure: Epidemiology Forecast to 2028" provides an overview of the risk factors and global trends of Heart Failure (HF) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan and China). This report includes a 10-year epidemiological forecast for the diagnosed incident cases of Heart Failure (HF) and diagnosed prevalent cases of Chronic Heart Failure (CHF) segmented by age, sex, and ejection fraction.

The report also includes Acute Heart Failure (AHF) hospitalizations, prevalent cases of Chronic Heart Failure (CHF) segmented by New York Heart Association (NYHA) functional Classes I-IV and American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Stages.

Scope

  • The Heart Failure Epidemiology Report and Model provide an overview of the risk factors and global trends of Heart Failure (HF) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan and China).
  • This report includes a 10-year epidemiological forecast for the diagnosed incident cases of HF and diagnosed prevalent cases of chronic heart failure (CHF) segmented by age, sex, and ejection fraction. It also includes acute HF (AHF) hospitalizations, prevalent cases of CHF segmented by New York Heart Association (NYHA) functional Classes I-IV and American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Stages. Additionally, the model includes a 10-year epidemiological forecast for various comorbidities of CHF.
  • The HF epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • - The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • - The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The HF Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HF market.
  • Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
  • Understand magnitude of HF population by its severity.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Heart Failure: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF
    • 3.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF by EF
    • 3.4.4 Forecast Assumptions and Methods: Acute Hospitalizations
    • 3.4.5 Forecast Assumptions and Methods: Acute Hospitalizations by Worsening CHF, Advanced HF, and De Novo HF
    • 3.4.6 Forecast Assumptions and Methods: Hospital Length of Stay
    • 3.4.7 Forecast Assumptions and Methods: Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
    • 3.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF
    • 3.4.9 Diagnosed Prevalent Cases of CHF by EF
    • 3.4.10 Diagnosed Prevalent Cases of CHF by NYHA Classes
    • 3.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF by ACCF/AHA Stages
  • 3.5 Epidemiological Forecast for Heart Failure (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of HF
    • 3.5.2 Age-Specific Diagnosed Incident Cases of HF
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of HF
    • 3.5.4 Diagnosed Incident Cases of HF by EF
    • 3.5.5 AHF Hospitalizations
    • 3.5.6 Hospital Length of Stay for AHF Hospitalization
    • 3.5.7 Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
    • 3.5.8 Diagnosed Prevalent Cases of CHF
    • 3.5.9 Diagnosed Prevalent Cases of CHF by EF
    • 3.5.10 Age-Specific Diagnosed Prevalent Cases of CHF
    • 3.5.11 Sex-Specific Diagnosed Prevalent Cases of CHF
    • 3.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class
    • 3.5.13 Diagnosed Prevalent Cases of CHF with PEF by NYHA Class
    • 3.5.14 Diagnosed Prevalent Cases of CHF with REF by NYHA Class
    • 3.5.15 Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

List of Tables

  • Table 1: Risk Factors and Comorbidities for HF
  • Table 2: NYHA Functional Classification for CHF (Classes I-IV)

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of HF, Both Sexes, All Ages, N, 2018 and 2028
  • Figure 2: 8MM, Diagnosed Prevalent Cases of CHF, Both Sexes, All Ages, N, 2018 and 2028
  • Figure 3: 8MM, Diagnosed Incidence of HF (Cases per 100,000 Population), Men and Women, All Ages, 2018
  • Figure 4: 8MM, Diagnosed Prevalence of CHF, Men and Women, All Ages, %, 2018
  • Figure 5: 8MM, Sources Used and Not Used to Forecast Diagnosed Incident Cases of HF
  • Figure 6: 8MM, Sources Used to Forecast Diagnosed Incident Cases of HF by EF
  • Figure 7: 8MM, Sources Used to Forecast Hospitalizations for AHF
  • Figure 8: 8MM, Sources Used to Forecast Hospitalizations for AHF by Worsening Chronic HF/Acute Decompensated, Advanced HF, and De Novo HF
  • Figure 9: 8MM, Sources Used to Forecast Hospital Readmissions (within 30 days) Post-Discharge After AHF Hospitalization
  • Figure 10: 8MM, Sources Used to Forecast Hospital Length of Stay for AHF Hospitalization
  • Figure 11: 8MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF
  • Figure 12: 8MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class
  • Figure 13: 8MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by ACCF/AHA Stages
  • Figure 14: 8MM, Diagnosed Incident Cases of HF, Both Sexes, All Ages, N, 2018
  • Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N, 2018
  • Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of HF, All Ages, N, 2018
  • Figure 17: 8MM, Diagnosed Incident Cases of HF by EF, Both Sexes, All Ages, N, 2018
  • Figure 18: 8MM, AHF Hospitalizations, Both Sexes, All Ages, N, 2018
  • Figure 19: 8MM, AHF Hospitalizations by Worsening Chronic HF, Advanced HF, and De Novo HF, Both Sexes, All Ages, N, 2018
  • Figure 20: 8MM, Hospital Length of Stay (Days) for AHF Hospitalization, Both Sexes, All Ages, N, 2018
  • Figure 21: 8MM, Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization, Both Sexes, All Ages, N, 2018
  • Figure 22: 8MM, Diagnosed Prevalent Cases of CHF, Both Sexes, All Ages, N, 2018
  • Figure 23: 8MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, All Ages, N, 2018
  • Figure 24: 8MM, Age-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, N, 2018
  • Figure 25: 8MM, Sex-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, All Ages, N, 2018
  • Figure 26: 8MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, All Ages, N, 2018
  • Figure 27: 8MM, Diagnosed Prevalent Cases of CHF with PEF by NYHA Class, Both Sexes, All Ages, N, 2018
  • Figure 28: 8MM, Diagnosed Prevalent Cases of CHF with REF by NYHA Class, Both Sexes, All Ages, N, 2018
  • Figure 29: 8MM, Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification, Both Sexes, All Ages, N, 2018
Back to Top